Verition Fund Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Verition Fund Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-110,000	Closed	-$7.61M	–	3329
2024 Q1	$7.61M	Buy	+110,000	New	+$7.56M	0.05%	447
2022 Q1	–	Sell	-75,000	Closed	-$3.93M	–	3094
2021 Q4	$3.93M	Buy	+75,000	New	+$3.15M	0.03%	478
2020 Q1	–	Sell	-598,000	Closed	-$20.5M	–	1122
2019 Q4	$20.5M	Buy	+598,000	New	+$7.18M	0.37%	53

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Verition Fund Management's ITCI Position: Q2 2025 in Review

Verition Fund Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 301,923 shares — an estimated $39.8M sold.

Verition Fund Management first reported a position in ITCI in Q3 2019 and held it in 17 quarters. The position peaked at $39.8M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Verition Fund Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Verition Fund Management sold 301,923 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $39.8M.
Verition Fund Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2019 and held it in 17 quarters.
Verition Fund Management's Intra-Cellular Therapies Inc. position peaked at $39.8M in Q1 2025.
3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.